QED Therapeutics, a BridgeBio Company
Clinical trials sponsored by QED Therapeutics, a BridgeBio Company, explained in plain language.
A biotech subsidiary of BridgeBio developing targeted therapies for genetic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study tracks growth in kids with rare bone disorder Results expected Oct 2026 (estimated) May already have reported ↗
- Could a daily pill boost growth in kids with hypochondroplasia? Results expected Jan 2027 (estimated) May already have reported ↗
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested a daily oral drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate compared to a placebo. The trial is now complete, and results will show wh…
Phase 3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested an oral drug called infigratinib in 84 children aged 3 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate. Children took the drug daily, and researchers measured height changes and side …
Phase 2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
No treatment, just tracking: PROPEL study watches how kids with achondroplasia grow
Knowledge-focused CompletedThis study followed 271 children with achondroplasia, ages 2.5 to 17, to understand their growth, medical issues, and quality of life over time. No medication or treatment was given. The goal was to gather natural history data to help design future clinical trials.
Sponsor: QED Therapeutics, a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC